Anxiety DisordersHealthy VolunteersSubstance Use Disorders (SUD)SchizophreniaPsilocybin

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

Pooled analysis of eight double‑blind, placebo‑controlled studies in 110 healthy volunteers found that psilocybin produced dose‑dependent profound changes in mood, perception, thought and self‑experience that most participants described as pleasurable and enriching, while acute dysphoric or panic reactions occurred only at the highest doses and were resolved with interpersonal support without pharmacological intervention. Follow‑up found no evidence of subsequent drug abuse, persistent perceptual disorders, prolonged psychosis or long‑term functional impairment, suggesting moderate doses in well‑prepared, closely monitored research settings carry an acceptable level of risk.

Authors

  • Franz Vollenweider
  • Matthias Kometer
  • Erich Studerus

Published

Journal of Psychopharmacology
meta Study

Abstract

Psilocybin and related hallucinogenic compounds are increasingly used in human research. However, due to limited information about potential subjective side effects, the controlled medical use of these compounds has remained controversial. We therefore analysed acute, short- and long-term subjective effects of psilocybin in healthy humans by pooling raw data from eight double-blind placebo-controlled experimental studies conducted between 1999 and 2008. The analysis included 110 healthy subjects who had received 1–4 oral doses of psilocybin (45–315 µg/kg body weight). Although psilocybin dose-dependently induced profound changes in mood, perception, thought and self-experience, most subjects described the experience as pleasurable, enriching and non-threatening. Acute adverse drug reactions, characterized by strong dysphoria and/or anxiety/panic, occurred only in the two highest dose conditions in a relatively small proportion of subjects. All acute adverse drug reactions were successfully managed by providing interpersonal support and did not need psychopharmacological intervention. Follow-up questionnaires indicated no subsequent drug abuse, persisting perception disorders, prolonged psychosis or other long-term impairment of functioning in any of our subjects. The results suggest that the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk.

Available with Blossom Pro

Research Summary of 'Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies'

Introduction

Psilocybin is a classical serotonergic hallucinogen found in Psilocybe mushrooms and has been used historically in ritual contexts and, more recently, in psychopharmacological research. Earlier clinical and experimental work showed that psilocybin produces an altered state of consciousness (ASC) characterised by marked changes in perception, mood, thought, and self-experience, and that its acute effects are generally shorter in duration than those of LSD. However, many early human studies lacked standardisation, adequate controls, follow-up, or sufficiently large and representative samples, leaving uncertainties about dose–response relations, the incidence of acute and subacute adverse reactions, and possible long-term psychological sequelae such as persisting perceptual disturbances or increased drug use. Studerus and colleagues set out to address these gaps by pooling raw data from eight double-blind, placebo-controlled experimental studies conducted in their laboratory between 1999 and 2008. Their aim was to describe acute, subacute (24 h), and long-term (8–16 months) subjective effects and side effects of psilocybin in healthy volunteers using validated psychometric instruments, and to evaluate dose–response relationships and the tolerability of the drug when administered in a controlled research setting.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (21)

Papers cited by this study that are also in Blossom

Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors

Carter, O., Burr, D. C., Pettigrew, J. D. et al. · Journal of Cognitive Neuroscience (2006)

Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans

Carter, O. L., Hasler, F. ;., Pettigrew, J. D. et al. · Psychopharmacology (2007)

Lysergic acid diethylamide: side effects and complications

Cohen, S. · Journal of Nervous and Mental Disease (1980)

The behavioral pharmacology of hallucinogens

Fantegrossi, W. E., Murnane, K. S., Reissig, C. J. · Biochemical Pharmacology (2007)

Serotonin research: contributions to understanding psychoses

Geyer, M. A., Vollenweider, F. X. · Trends in Pharmacological Sciences (2008)

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior

Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)

818 cited
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Show all 21 references
Hallucinogen persisting perception disorder: what do we know after 50 years?

Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (2003)

204 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder

Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)

The pharmacology of psilocybin

Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)

Increased Activation of Indirect Semantic Associations under Psilocybin

Spitzer, M., Thimm, M., Hermle, L. et al. · Biological Psychiatry (1996)

90 cited
Effects of varied doses of psilocybin on time interval reproduction in human subjects

Wittmann, M., Hasler, F., Vollenweider, F. X. · Neuroscience Letters (2008)

70 cited
Effects of psilocybin on time perception and temporal control of behaviour in humans

Wittmann, M., Carter, O., Hasler, F. et al. · Journal of Psychopharmacology (2007)

212 cited

Cited By (157)

Papers in Blossom that reference this study

Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression

Morel, N. S., Stenbaek, D. S., Lundberg, J. et al. · BMC Medical Education (2026)

Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study

Mallevays, M., Fuet, L., Danon, M. et al. · MedRvix (2026)

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial

Meikle, S., Carter, O., Liknaitzky, P. et al. · Therapeutic Advances in Psychopharmacology (2025)

Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats

Vejmola, C., Šíchová, K., Syrová, K. et al. · Biological Psychiatry (2025)

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression

Brudner, R. M., Kaczmarek, E., Blainey, M. G. et al. · Journal of Psychopharmacology (2025)

Show all 157 papers
The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience

Tolle, H. M., Farah, J. C., Mallaroni, P. et al. · Network Neuroscience (2024)

Psychiatric risks for worsened mental health after psychedelic use

Marrocu, A., Kettner, H., Weiss, B. et al. · Journal of Psychopharmacology (2024)

41 cited
Increases in Aesthetic Experience Following Ayahuasca Use: A Prospective, Naturalistic Study

Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Humanistic Psychology (2024)

Effects of DMT on mental health outcomes in healthy volunteers

Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)

29 cited
Effects of hallucinogenic drugs on the human heart

Neumann, J., Dhein, S., Kirchhefer, U. et al. · Frontiers in Pharmacology (2024)

Cellular rules underlying psychedelic control of prefrontal pyramidal neurons

Ekins, T. G., Brooks, I., Kailasa, S. et al. · Biorxiv (2023)

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis

Haikazian, S., Chen-Li, D., Johnson, D. et al. · Psychiatry Research (2023)

The ego in psychedelic drug action - ego defenses, ego boundaries, and the therapeutic role of regression

Buchborn, T., Kettner, H., Kartner, L. et al. · Frontiers in Neuroscience (2023)

Case analysis of long-term negative psychological responses to psychedelics

Bremler, R., Katati, N., Shergill, P. et al. · Scientific Reports (2023)

The Potential of Psychedelics for the Treatment of Episodic Migraine

Schindler, E. A. D. · Current Pain and Headache Reports (2023)

Effects of ayahuasca on gratitude and relationships with nature: An open-label, naturalistic study

Bloesch, E. K., Davis, A. K., Domoff, S. E. et al. · Psyarxiv (2023)

Transpersonal Ecodelia: Surveying Psychedelically Induced Biophilia

Luke, D., Gandy, S., Irvine, A. et al. · Psychoactives (2023)

17 cited
The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

Kinderlehrer, D. A. · International Medical Case Reports Journal (2023)

Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness

Forstmann, M., Kettner, H. S., Sagioglou, C. et al. · Journal of Psychopharmacology (2023)

Altered States of Consciousness During Ceremonial San Pedro Use

Bohn, A., Kiggen, M. H. H., Uthaug, M. V. et al. · International Journal for the Psychology of Religion (2022)

Predictors of attitudes toward psychedelics among psychologists in the USA

Luoma, J. B., Pilecki, B., Davis, A. K. et al. · Drugs Education Prevention and Policy (2022)

11 cited
Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study

Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)

Pharmacokinetics of N,N-dimethyltryptamine in Humans

Good, M., Joel, Z., Benway, T. et al. · European Journal of Pharmacology (2022)

LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility

Wießner, I., Olivieri, R., Falchi, M. et al. · European Neuropsychopharmacology (2022)

Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy

Sekula, A. D., Downey, L., Puspanathan, P. · Frontiers in Psychology (2022)

19 cited
Classic Psychedelic Drugs: Update on Biological Mechanisms

Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)

71 cited
Human behavioral pharmacology of psychedelics

Strickland, J. C., Johnson, M. W. · Advances in Pharmacology (2022)

5 cited
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)

Models of psychedelic drug action: modulation of cortical-subcortical circuits

Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)

Low-dose LSD and the stream of thought: Increased Discontinuity of Mind, Deep Thoughts and abstract flow

Maia, L. O., Feilding, A., Ribeiro, S. et al. · Psychopharmacology (2021)

From Psychiatry to Neurology: Psychedelics as Prospective Therapeutics for Neurodegenerative Disorders

Nichols, C. D., Wiatr, K., Figiel, M. et al. · Journal of Neurochemistry (2021)

63 cited
Psychedelics, sociality, and human evolution

Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)

The effects of tryptamine psychedelics in the brain: a meta-analysis of functional and review of molecular imaging studies

Castelhano, J. M., Lima, G. M., Teixeira, M. et al. · Frontiers in Pharmacology (2021)

Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States

Davis, A. K., Agin-Liebes, G. I., España, M. et al. · Journal of Psychoactive Drugs (2021)

Cancer Healthcare Workers' Perceptions toward Psychedelic-Assisted Therapy: A Preliminary Investigation

Reynolds, L. M, Stack, A., Akroyd, A., Sundram, F. et al. · International Journal of Environmental Research and Public Health (2021)

22 cited
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa

Rodan, S., Aouad, P., McGregor, I. S. et al. · OBM Neurobiology (2021)

Use of psilocybin (“mushrooms”) among US adults: 2015-2018

Yockey, R. A., King, K. A. · Journal of Psychedelic Studies (2021)

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)

1015 cited
Spontaneous and deliberate creative cognition during and after psilocybin exposure

Mason, N. L., Kuypers, K. P. C., Reckweg, J. T. et al. · Translational Psychiatry (2021)

86 cited
Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Systematic Review of Published Case Studies

Gard, D. E., Pleet, M. M., Bradley, E. R. et al. · Journal of Affective Disorders (2021)

Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice

Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)

55 cited
Acute Psychological Adverse Reactions in First-Time Ritual Ayahuasca Users

Gómez-Sousa, M., Jiménez-Garrido, D. F., Ona, G. et al. · Journal of Clinical Psychopharmacology (2021)

18 cited
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin

Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H. et al. · Neurotherapeutics (2021)

The History of Psychedelics in Psychiatry

Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health

Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)

Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison

Leptourgos, P., Fortier-Davy, M., Carhart-Harris, R. L. et al. · Schizophrenia Bulletin (2020)

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)

The therapeutic potential of microdosing psychedelics in depression

Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)

Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin

Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)

73 cited
Long-term effects of psychedelic drugs: A systematic review

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)

Tripping on nothing: placebo psychedelics and contextual factors

Olson, J. A., Suissa-Rocheleau, L., Lifshitz, M. et al. · Psychopharmacology (2020)

Natural Psychoplastogens As Antidepressant Agents

Benko, J., Vranková, S. · Molecules (2020)

Psychedelics and Psychedelic-Assisted Psychotherapy

Reiff, C. M., Richman, E. E., Nemeroff, C. B. et al. · American Journal of Psychiatry (2020)

Acute effects of psilocybin on glutamate concentration levels, functional connectivity and subjective state

Mason, N. L., Feilding, A., Ramaekers, J. G. · European Neuropsychopharmacology (2020)

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)

From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner

Kettner, H., Gandy, S., Haijen, E. C. H. M. et al. · International Journal of Environmental Research and Public Health (2019)

131 cited
Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat

Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)

126 cited
Acute effects of lysergic acid diethylamide (LSD) on resting brain function

Felix, M., Stefan, B. · Swiss Medical Weekly (2019)

Predicting responses to psychedelics: a prospective study

Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)

339 cited
49 cited
Psychedelics, meditation, and self-consciousness

Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)

DARK Classics in Chemical Neuroscience: Psilocybin

Geiger, H. A., Wurst, M. G., Daniels, R. N. · ACS Chemical Neuroscience (2018)

High dose psilocybin is associated with positive subjective effects in healthy volunteers

Nicholas, C. R., Henriquez, K. M., Gassman, M. C. et al. · Journal of Psychopharmacology (2018)

61 cited
Unifying theories of psychedelic drug effects

Swanson, L. R. · Frontiers in Pharmacology (2018)

Serotonergic psychedelics and personality: A systematic review of contemporary research

Bouso, J. C., Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2018)

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review

Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)

Psychiatry & the psychedelic drugs. Past, present & future

Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)

LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation

Sumiyoshi, T., Kraehenmann, R., Pokorny, D. et al. · Frontiers in Pharmacology (2017)

Neuroticism is associated with challenging experiences with psilocybin mushrooms

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Personality and Individual Differences (2017)

78 cited
Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music

Barrett, F. S., Preller, K. H., Herdener, M. et al. · Cerebral Cortex (2017)

Long-lasting subjective effects of LSD in normal subjects

Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)

68 cited
Effect of psilocybin on empathy and moral decision-making

Pokorny, T., Preller, K. H., Kometer, M. et al. · International Journal of Neuropsychopharmacology (2017)

155 cited
Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress

Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)

130 cited
Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis

Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)

Modern clinical research on LSD

Liechti, M. E. · Neuropsychopharmacology (2017)

Psychedelics, personality and political perspectives

Nour, M. R., Evans, J., Carhart-Harris, R. L. · Journal of Psychoactive Drugs (2017)

164 cited
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation

Kraehenmann, R. ;., Pokorny, D. ;., Vollenweider, L. ;. et al. · Psychopharmacology (2017)

138 cited
Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report

Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Journal of Psychedelic Studies (2017)

6 cited
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Brown, R. T., Nicholas, C. R., Cozzi, N. V. et al. · Clinical Pharmacokinetics (2017)

Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Classical hallucinogens and neuroimaging: A systematic review of human studies: hallucinogens and neuroimaging

Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Neuroscience and Biobehavioral Reviews (2016)

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

Clinical Applications of Hallucinogens: A Review

Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)

174 cited
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)

Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)

Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)

Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies

Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)

130 cited
The paradoxical psychological effects of lysergic acid diethylamide (LSD)

Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)

253 cited
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Effects of MDMA on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting

Baggot, M. J., Coyle, J. R., Siegrist, J. D. et al. · Journal of Psychopharmacology (2015)

2 cited
Mania following use of ibogaine: A case series

Marta, C. J., Ryan, W. C., Kopelowicz, A. et al. · The American Journal on Addictions (2015)

50 cited
Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?

Rolland, B., Jardri, R., Amad, A. et al. · BioMed Research International (2014)

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)

Therapeutic infusions of ketamine: do the psychoactive effects matter?

Dakwar, E., Anerella, C., Hart, C. L. et al. · Drug and Alcohol Dependence (2014)

Psilocybin - Summary of knowledge and new perspectives

Tylš, F., Páleníček, T., Horacek, J. · European Neuropsychopharmacology (2013)

The induction of synaesthesia with chemical agents: a systematic review

Luke, D. P., Terhune, D. B. · Frontiers in Psychology (2013)

Psychedelics and mental health: a population study

Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)

Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects

Maclean, K. A., Johnson, M. W., Reissig, C. J. et al. · Psychopharmacology (2012)

Genuine and drug-induced synesthesia: a comparison

Sinke, C., Halpern, J. H., Zedler, M. et al. · Consciousness and Cognition (2012)

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers

Johnson, M. W., Sewell, R. A., Griffiths, R. R. · Drug and Alcohol Dependence (2012)

Prediction of psilocybin response in healthy volunteers

Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers

Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)

Harm potential of magic mushroom use: A review

Van Amsterdam, J., Opperhuizen, A., Van Den Brink, W. · Regulatory Toxicology and Pharmacology (2011)

169 cited
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

A brief survey of drug use and other activities preceding mystical-religious experiences

Baggot, M. J. · International Journal for the Psychology of Religion (2000)

71 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.